AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly. The extended collaboration will enrich AstraZeneca’s immuno-oncology (IO) portfolio with pre-clinical and clinical potential new medicines.
{iframe}https://pipelinereview.com/index.php/2018102369493/More-News/AstraZeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-Innate-Pharma.html{/iframe}